Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

verfasst von: Zoltán Lőcsei, MD, Katalin Hideghéty, MD, PhD, Dr. habil. Zsuzsanna Kahán, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

PET or PET/CT mostly utilizing the tracer [18F]fluorodeoxyglucose (18FDG) are unique imaging methods for the detection of breast cancers with increased glucolytic activity. PET/CT simultaneously provides anatomic and metabolic information by detecting increased glucose uptake. PET/CT may provide extra information on stage that can be utilized in certain cases during treatment decision making. PET/CT is a very sensitive imaging option to detect lymph node involvement or distant metastasis for which information is needed in selected cases. In the neoadjuvant or metastatic setting, PET or PET/CT may serve as a valuable noninvasive option for investigating chemosensitivity and monitoring the effectiveness of systemic therapy. Its use, however, should be reserved for particular cases with diagnostic uncertainty in the routine management of breast cancer.
Molecular imaging with non-FDG PET tracers developed using advanced molecular and cell biology techniques widens the possibility to study the pathological molecular events and processes in breast cancer, and may be used for the detection of key molecules to be targeted by pharmaceutical interventions; the method provides new possibility to evaluate novel drugs.
Literatur
1.
Zurück zum Zitat Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011 Mar 15;103(4):348–57.CrossRefPubMed Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011 Mar 15;103(4):348–57.CrossRefPubMed
2.
Zurück zum Zitat Robertson IJ, Hard F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011 Jul 30. Epub ahead of print. Robertson IJ, Hard F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011 Jul 30. Epub ahead of print.
3.
Zurück zum Zitat Monzawa S, Adachi S, Suzuki K, et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastases: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl MED. 2009;23(10):855–61.CrossRefPubMed Monzawa S, Adachi S, Suzuki K, et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastases: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl MED. 2009;23(10):855–61.CrossRefPubMed
4.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165CrossRefPubMed Ueda S, Tsuda H, Asakawa H, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165CrossRefPubMed
5.
Zurück zum Zitat Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.CrossRefPubMed Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.CrossRefPubMed
6.
Zurück zum Zitat Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50(2):231–8.CrossRefPubMed Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50(2):231–8.CrossRefPubMed
7.
Zurück zum Zitat Alberini JL, Lerebours F, Wartski M, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009 Nov 1;115(21):5038–47.CrossRefPubMed Alberini JL, Lerebours F, Wartski M, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009 Nov 1;115(21):5038–47.CrossRefPubMed
8.
Zurück zum Zitat Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):695–704.CrossRefPubMed Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):695–704.CrossRefPubMed
9.
Zurück zum Zitat Groheux D, Giacchetti S, Espié M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med. 2011;52:1526–34.CrossRefPubMed Groheux D, Giacchetti S, Espié M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med. 2011;52:1526–34.CrossRefPubMed
10.
Zurück zum Zitat Koolen BB, Vegt E, Rutgers EJ, Vogel WV, et al. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Ann Nucl Med. 2011 Sept 28. Epub ahead of print. Koolen BB, Vegt E, Rutgers EJ, Vogel WV, et al. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Ann Nucl Med. 2011 Sept 28. Epub ahead of print.
11.
Zurück zum Zitat Hahn S, Heusner T, Kümmel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011 Nov 1;52(9):1009–14.CrossRefPubMed Hahn S, Heusner T, Kümmel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011 Nov 1;52(9):1009–14.CrossRefPubMed
12.
Zurück zum Zitat Niikiura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compered with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16(8):1111–9.CrossRef Niikiura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compered with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16(8):1111–9.CrossRef
13.
Zurück zum Zitat Ohsumi S, Inoue T, Kiyoto S, et al. Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow up of postoperatve brast cancer patients. Breast Cancer Res Treat. 2011. Epub ahead of print. Ohsumi S, Inoue T, Kiyoto S, et al. Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow up of postoperatve brast cancer patients. Breast Cancer Res Treat. 2011. Epub ahead of print.
14.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG-PET/CT) in primary breast cancer. J Clin Oncol. 2008;38(4):250–8. Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG-PET/CT) in primary breast cancer. J Clin Oncol. 2008;38(4):250–8.
15.
Zurück zum Zitat Ueda S, Tsuda H, Saeki T, et al. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J. 2010;16(6):660–2.CrossRefPubMed Ueda S, Tsuda H, Saeki T, et al. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J. 2010;16(6):660–2.CrossRefPubMed
16.
Zurück zum Zitat Ueda S, Tsuda H, Saeki T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011;18(4):299–308.CrossRefPubMed Ueda S, Tsuda H, Saeki T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011;18(4):299–308.CrossRefPubMed
17.
Zurück zum Zitat Wang CL, MacDonald LR, Rogers JV, et al. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. AJR Am J Roentgenol. 2011;197(2):W247–55.CrossRefPubMed Wang CL, MacDonald LR, Rogers JV, et al. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. AJR Am J Roentgenol. 2011;197(2):W247–55.CrossRefPubMed
18.
Zurück zum Zitat Ueda S, Saeki T, Shigekawa T, et al. (18)F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol. 2011 Aug 10. Epub ahead of print. Ueda S, Saeki T, Shigekawa T, et al. (18)F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol. 2011 Aug 10. Epub ahead of print.
19.
Zurück zum Zitat Keam B, Im SA, Koh Y, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011 Oct 20;11:452.CrossRefPubMed Keam B, Im SA, Koh Y, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011 Oct 20;11:452.CrossRefPubMed
20.
Zurück zum Zitat Kumar A, Kumar R, Seenu V, et al. The role of (18)F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19:1347–57.CrossRefPubMed Kumar A, Kumar R, Seenu V, et al. The role of (18)F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19:1347–57.CrossRefPubMed
21.
Zurück zum Zitat Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007,34:1915–24.CrossRefPubMed Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007,34:1915–24.CrossRefPubMed
22.
Zurück zum Zitat Duch J, Fuster D, Munoz M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–7.CrossRefPubMed Duch J, Fuster D, Munoz M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–7.CrossRefPubMed
23.
Zurück zum Zitat Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449–57.CrossRefPubMed Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449–57.CrossRefPubMed
24.
Zurück zum Zitat Jung SY, Kim SK, Nam BH, et al. Prognostic impact of [(18)F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2009;17:247–53.CrossRefPubMed Jung SY, Kim SK, Nam BH, et al. Prognostic impact of [(18)F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2009;17:247–53.CrossRefPubMed
25.
Zurück zum Zitat Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.CrossRefPubMed Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.CrossRefPubMed
26.
Zurück zum Zitat Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.CrossRefPubMed Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.CrossRefPubMed
27.
Zurück zum Zitat Padmanabhan P, Goggi J, Bejot R, et al. Molecular targeting of breast cancer: imaging and therapy. Curr Pharm Biotechnol. 2011;12(4):528–38.CrossRefPubMed Padmanabhan P, Goggi J, Bejot R, et al. Molecular targeting of breast cancer: imaging and therapy. Curr Pharm Biotechnol. 2011;12(4):528–38.CrossRefPubMed
28.
Zurück zum Zitat Sekar TV, Dhanabalan A, Paulmurugan R, et al. Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol. 2011;12(4):508–27.CrossRefPubMed Sekar TV, Dhanabalan A, Paulmurugan R, et al. Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol. 2011;12(4):508–27.CrossRefPubMed
29.
Zurück zum Zitat Tomasi G, Kenny L, Mauri F, et al. Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38(12):2186–97.CrossRefPubMed Tomasi G, Kenny L, Mauri F, et al. Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38(12):2186–97.CrossRefPubMed
30.
Zurück zum Zitat Hatt M, Cheze-Le Rest C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51(9):1368–76.CrossRefPubMed Hatt M, Cheze-Le Rest C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51(9):1368–76.CrossRefPubMed
31.
Zurück zum Zitat Krause BJ, Schwarzenböck S, Schwaiger M. Tracers in oncology—preclinical and clinical evaluation. Nuklearmedizin. 2010;49(Suppl 1):S41–5.PubMed Krause BJ, Schwarzenböck S, Schwaiger M. Tracers in oncology—preclinical and clinical evaluation. Nuklearmedizin. 2010;49(Suppl 1):S41–5.PubMed
32.
33.
Zurück zum Zitat Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009 Sept 1;15(17):5503–10.CrossRefPubMed Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009 Sept 1;15(17):5503–10.CrossRefPubMed
34.
Zurück zum Zitat Contractor KB, Kenny LM, Stebbing J, et al. Biological basis of (11C)choline-positron emission tomography in patients with breastcancer: comparison with (18F)fluorothymidine positron emission tomography. Nucl Med Commun. 2011;32(11):997–1004.CrossRefPubMed Contractor KB, Kenny LM, Stebbing J, et al. Biological basis of (11C)choline-positron emission tomography in patients with breastcancer: comparison with (18F)fluorothymidine positron emission tomography. Nucl Med Commun. 2011;32(11):997–1004.CrossRefPubMed
35.
Zurück zum Zitat Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(Suppl 3):S66–73.CrossRefPubMed Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(Suppl 3):S66–73.CrossRefPubMed
36.
Zurück zum Zitat Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799–805.CrossRefPubMed Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799–805.CrossRefPubMed
37.
Zurück zum Zitat Kurland BF, Peterson LM, Lee JH, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med. 2011;52(10):1541–9.CrossRefPubMed Kurland BF, Peterson LM, Lee JH, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med. 2011;52(10):1541–9.CrossRefPubMed
38.
Zurück zum Zitat Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010;37(3):289–97.CrossRefPubMed Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010;37(3):289–97.CrossRefPubMed
39.
Zurück zum Zitat Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastaticbreast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.CrossRefPubMed Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastaticbreast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.CrossRefPubMed
40.
Zurück zum Zitat Manning K, Tepfer B, Goldklang G, et al. Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group. Mol Imaging Biol. 2007;9(6):324–32.CrossRefPubMed Manning K, Tepfer B, Goldklang G, et al. Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group. Mol Imaging Biol. 2007;9(6):324–32.CrossRefPubMed
Metadaten
Titel
The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer
verfasst von
Zoltán Lőcsei, MD
Katalin Hideghéty, MD, PhD
Dr. habil. Zsuzsanna Kahán, MD, PhD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0007-2

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe